First Warning Systems Breast Cancer Tumor Development Video Shows Predictive Analytics Impact on Women’s Health

First Warning Systems, Inc. announces the availability of its Breast Cancer Tumor Development Video showing a timeline for cell abnormalities that develop up to six years prior to tumor presentation. “This video can be viewed on our website, www.firstwarningsystems.com. The video sets forth the core science underlying our ability to predict the likelihood of breast cancer development,” says Jim Holmes, First Warning CEO. “It is an established fact that cancer cells, on average, double approximately every 128 days (doubling times vary with the type of tumor). The video shows when a .2 cm tumor would have begun its cell abnormality and can be measured by temperature variations. The temperature variations identify abnormal cell activity up to six years prior to current imaging or thermography technology. The early identification of abnormal cell activity provides a much better opportunity to manage disease progression,” adds Holmes.

“The video also shows the direction of our product development, anticipating a wearable garment,” states Matt Benardis, Operations Consultant. “Such a garment opens up a number of additional markets in addition to having the First Warning system available from the clinician during the women’s annual physical.”

About First Warning Systems Process

Temperature readings of breast tissue create Dynamic Thermal Finger Prints (DTFP) which are correlated to dysfunctional circadian genes. Multiple bioinformatics algorithms compare DTFPs to the circadian gene protein profiles to identify breast tissue abnormalities at different stages of development of disturbed breast cancerous cells. FWS’s proprietary Predictive Analytics analyses patient breast health data to deliver an interpretation report to the primary care physician with industry leading 90% accuracy. The FWS process is the only detection process that identifies abnormalities before a tumor presents, can be used by a primary care physician. The capital investment is very competitive, also requires a minimal data interpretation fee.

About First Warning Systems

First Warning Systems, (FWS) founded in 2008, is based in Reno, NV. FWS’s principal shareholder is Lifeline Biotechnologies, Inc (OTC Market: LLBO). FWS holds the exclusive development, manufacturing and marketing worldwide license from Lifeline, to commercialize the intellectual property. The FWS product line is a device and process that detects breast tissue abnormalities which lead to health risk assessment and management and potentially, breast cancer. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. FWS expects to obtain a Euro CE Mark for marketing in the UK, EU and Russia markets next year. For more information check www.firstwarningsystems.com.

Lifeline Biotech (CE) (USOTC:LLBO)
Historical Stock Chart
From Jun 2024 to Jul 2024